ORIGINAL ARTICLE

FUTURE JOURNAL OF PHARMACEUTICALS AND HEALTH SCIENCES

Published by Pharma Springs Publication Journal Home Page: https://pharmasprings.com/fjphs

Preparation of Colon-Targeted Avermectins Tablets and its Release Properties *in vitro* Studies

Shaik Nissar[1], Pradeep Kumar M[*1], Chandrakala P[1], Hari Kumar C[2]

[1]Department of Pharmaceutical Technology, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (V), Sidhout (M), YSR Kadapa-516 247, Andhra Pradesh, India
[2]Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (V), Sidhout (M), YSR Kadapa-516 247, Andhra Pradesh, India

Article History:

Received on: 05 Dec 2021
Revised on: 21 Dec 2021
Accepted on: 22 Dec 2021

Keywords:

Colon-Targeted Drug Delivery,
Eudragit L-100,
CAP,
Avermectins,
In-vitro Studies

ABSTRACT

The purpose of the current written report sniffs out swell colon targeted drug delivery system provided that Avermectins using Eudragit L-100 and cellulose acetate phthalate. The avermectins are a sequence of drugs plus pesticides used to treat parasitic worms. Avermectins serve as unexpectedly absorbed succeeding oral administration and its half-life will be 0.5 to 2.5 hrs which may be a restriction given that Avermectins. Due to less $t_{1/2}$ doses of Avermectins composed grave responses within the GIT. Therefore matrix formulation involving proportions consisting of eudragit L-100 and CAP are planned out with the aid of a direct compression technique. The *in-vitro* drug release profile in dissolution maintain temperature at 37 ± 0.5^{o}C in a buffer because 19hrs. The Eudragit L-100 than by method using CAP and 1:1 ratios regarding eudragit L-100 and CAP. Succeeding 24 hrs % drug releases for the reason that AM-3 was found to be 98.2%. Drug release kinetics revealed that drug release from AM-3 tends to follow the Higuchi model along with fickian diffusion.

*Corresponding Author

Name: Pradeep Kumar M
Phone: +91 9966466281
Email: pradeepbadvel98@gmail.com

eISSN: 2583-116X pISSN:

DOI: https://doi.org/10.26452/fjphs.v2i1.167

Production and Hosted by

Pharmasprings.com

© 2022 | All rights reserved.

INTRODUCTION

Oral delivery of drugs up to the colon will be valuable in the treatment going from diseases containing colon by which high local concentration might be achieved while minimizing adverse effects that fact occur due up to relinquishing containing medicines in the upper GIT or excess systemic absorption [1]. The colon might be seeking interest as site the place poorly absorbed drug molecules may need a touch-up bioavailability. The region going from colon can be accepted barely less hostile surroundings and much not more diversity and strength of utilization on the stomach and small intestine [2]. The avermectins will be a sequence going from medicinal drugs and pesticides routine. They seem to be a group of 16-membered macrocyclic lactone derivatives products together with potent anthelmintic and insecticidal features [3].

MATERIALS

Avermectins was a gift sample from drug India Pvt. Ltd, Hyderabad. CAP and Eudragit L-100 was purchased from drug India Pvt. Ltd, Hyderabad. Microcrystalline Cellulose, Magnesium stearate, and talc was purchased from B.M.R Chemicals, Hyderabad other materials and solvents used were of analytical grade.

Methodology

Compatibility Studies

Sample concentration in KBr must be within the lim

Table 1: Formulation of Avermectins Colon Targeted Tablets

Formulation code	Avermectins (mg)	MCC (mg)	Magnesium Stearate (mg)	Talc (mg)
AM-1	150	690	60	100
AM-2	150	690	60	100
AM-3	150	690	60	100
AM-4	150	690	60	100
AM-5	150	690	60	100
AM-6	150	690	60	100

Table 2: FTIR Functional Groups

FTIR Spectrum	C-Cl stretch	C–N stretch	O–H stretch	C–H stretch
Drug	741.82	1216.16	2672.8	2872.1
Cellulose acetate phthalate	742.87	1069.93	3463.35	2912.1
Eudragit	831.71	1159.39	2998.51	2953.78
Mixture	751.82	1250.53	2671.98	2861.2

Table 3: Pre compression parameters for Avermectins drug powders

Formulations	Bulk density(g/cm^3)	Tapped density(g/cm^3)	Hausner's ratio (%)	Carr's index (%)	Angle of repose(θ)
AM-1	0.55	0.64	1.18	13.56	$24^o.84^1$
AM-2	0.56	0.64	1.13	11.87	$23^o.23^1$
AM-3	0.54	0.62	1.12	12.18	$22^o.29^1$
AM-4	0.53	0.67	1.14	11.18	$23^o.23^1$
AM-5	0.52	0.62	1.15	13.17	$21^o.84^1$
AM-6	0.55	0.63	1.13	11.72	$21^o.26^1$

Table 4: Post Formulation Studies of Avermectins Coated Tablets

Sl. No.	Parameter	AM-1	AM-2	AM-3	AM-4	AM-5	AM-6
1	Thickness (mm)	5.4	5.2	5.3	5.1	5.2	5.3
2	Weight variation (mg)	1005.5 + 0.14	1009.6 + 0.28	1010.3 + 0.60	1012.5 + 0.29	1014.4 + 0.19	1013.5 + 0.17
3	Hardness (kg/cm^2)	4.7	4.9	4.8	5.5	5.5	5.4
4	Friability (%)	0.68%	0.75%	0.72%	0.85%	0.82%	0.89%

its. The thickness of the pellet is way more than a liquescent film, so a sample with a low concentration is required. Too high concentration generally leads to difficulties in obtaining clear pellets [4].

Formulation

The drug (150mg/tablet) and other excipients used by this same formulation managed to pass through 60 sieves ahead of compression. The Particle blends were ready that used a cone mixer given that 15 min. At the moment talcum used to be added and mixed given that another 5 min [5].

The desired amount of their additives given that getting ready the mixtures have indeed been compressed utilizing cabmach rotary tablet grinding machine fitted with 13mm capsule molded, concave punches [Table 1].

Table 5: *In-vitro* Release of Drug Data for Avermectins Tablets

Time (Hrs)	AM-1	AM-2	AM-3	AM-4	AM-5	AM-6
1	4.7	3.5	3.2	4.7	3.2	2.5
2	7.3	6.4	5.2	7.6	5.4	4.5
5	17.6	8.6	8.3	19.4	13.0	11.7
6	26.8	25.3	22.5	25.3	24.7	24.7
9	39.6	33.1	31.3	40.1	35.5	35.5
12	60.3	56.6	45.5	57.5	47.5	49.7
15	72.6	70.8	62.6	73.2	68.8	67.3
18	80.5	84.4	72.5	87.3	90.4	79.5
21	96.5	91.4	86.3	95.6	88.2	89.4
24		96.4	98.2		97.2	94.1

Table 6: Parameters and Determination Coefficients of Release Profile from Avermectins Colon Targeted Tablets

Formulation code	Correlation Coefficient values (r^2)				Diffusion Exponent value (n)
	Zero Order	First Order	Higuchi	Korsmeyer-peppas	
AM-1	0.97	0.97	0.95	0.92	0.18
AM-2	0.98	0.85	0.96	0.91	0.19
AM-3	0.99	0.87	0.98	0.92	0.18
AM-4	0.98	0.96	0.96	0.93	0.17
AM-5	0.98	0.94	0.97	0.96	0.17
AM-6	0.98	0.95	0.97	0.92	0.18

Table 7: Stability studies *In-vitro* dissolution profile of AM-3

Time	% drug release of AM-3		
	Batch-1 (25°C/60%RH)	Batch-2 (40°C/70%RH)	Batch-3 (60°C/80%RH)
1	3.2	3.1	3.2
2	5.2	5.3	5.4
3	8.3	8.4	8.5
6	22.5	22.6	22.7
9	31.3	31.4	32.5
12	45.5	46.6	47.7
15	62.6	63.7	63.8
18	72.5	73.6	73.6
21	86.3	87.2	87.3
24	98.2	98.3	98.3



Figure 1: FTIR Spectrum of Drug, CAP, Eudragit, and Mixture

Pre- compression Parameters

The powdered blend was analyzed for flow properties as follows [6].

Angle of repose: $\theta = \tan^{-1}$ (h/r)

Bulk density = Weight of powder/ Bulk volume

Tapped density = Weight of powder/ Tapped volume

Carr's Index (I) = (Tapped Density - Bulk Density)/ (Tapped Density) x100

Hausner's ratio = Tapped density/ Bulk density

Post Compression Parameters

Tablet Dimensions

5 tablets were taken and their thickness was measured with the help of Vernier calipers [7].

Hardness

The pressure was gradually increased for breaking the tablet [8]. Hardness Limits: 4-6kg/sq.cm.

Friability

A Friability test was performed to predict the tablet's ability to e dure any abrasions in packaging, handling & transport. Roche friabilator is most commonly used instrument was routine watch over friability of the tablet [9]. 20 tablets have been reweighed from every batch and situated in a friabillator and set to rotate at an rpm of 25 for 4 min. The percentage of friability was calculated using the formula.

$$Friability = ((weight\ of\ tablet\ before\ test - weight\ of\ tablet\ after\ test)/ weight\ of\ tablet\ before\ the\ test) \times 100$$

Drug Content

At Random, 20 tablets have been grassed, reweighed & made within the powder. Similar to 25 mg used to be weighed exactly and subsequent molten in 100ml of 0.1N HCl and so solution turned into agitated carefully [10]. The absorbance of the current solution used to be measured at 365 nm.

In vitro Dissolution Studies

That is conveyed mostly by utilizing Paddle type Apparatus at 50rpm. The 900 ml of medium with pH 6.8 buffer constitute the dissolution medium become serviceable at 37±0.5°C [11]. An equivalent quantity of fresh dissolution medium was replaced

without delay after the withdrawal of test sample.

Mathematical modeling for drug release profile

The data acquired from the *in vitro* dissolution tests obtain the kinetic track record analysis [12].

Zero-order kinetics: $Q_t = Q_o + K_o t$

First-order kinetics: $Q_t = log\ Q_o + K_1 t/2.303$

Higuchi model: $Q_t = K_H \cdot t^{1/2}$

Korsmeyer-Peppas release model: $Mt / M_\infty = K \cdot t^n$

Stability Studies

The stability literature review as per an aspect of their approach for 3 months in different speeded up accelerated temperature plus humidity [13] situations of 25°C/60%RH, 40°C/70%RH, 60°C/80%RH.

RESULTS AND DISCUSSION

FT- IR Studies

From drug excipient compatibility trend analysis, we referred to the absence of interactions between pure drug and excipients [Figure 1 and Table 2].

Micromeritic Parameters

The blend of materials became tested as characteristics like angles of repose, bulk densities, tapped density, Compressibility index have good flow characteristics and flow rates [Table 3].

Post-Compression Evaluation Parameters

The thickness of all the formulations encounters ultimate within the range of 5.1 to 5.4mm. Weight variation within the range of 1005.5 0.14 mg to 1014.4 + 0.19mg. The Hardness of all the formulations encounters best within the range consisting of 4.7 to 5.5 kg/cm^2. Friability of tablet was range from 0.68 % to 0.89 % [Table 4].

***In-Vitro* Dissolution Studies**

Out of the nine formulation AM-3 flaunted to absolute best release chart in 24 hrs with 98.2% drug discharge and the consequences tend to be tabulated in Table 5.

***In-Vitro* Drug Release Kinetics**

According to the very best regression integrity (r^2), the best-fit role model for AM1 to AM6 used to be zero-order and for AM3 it was Higuchi Model [Table 6].

Stability Studies

The overall stability test was conducted along with AM-3 which explains well thought out ultimate the best. The formulation was once analyzed since the dissolution chart for reason that a period going from 12 weeks [Table 7, Figure 2]. The results are observed in different batches -1, 2 & 3.



Figure 2: Stability Data Graph for AM-3 Formulation

CONCLUSION

All the pre-compressional and post-compressional variables had already been assessed and considered to be within limits. Among all the preparation AM-3 with 5 % Eudragit L-100 appeared as afterlife best one because it displays the almost percent drug release of 98.2 %. *In vitro* kinetics for AM-3 exhibited to regarding which the drug surrendering process was discovered to also be fickian diffusion.

ACKNOWLEDGEMENT

I would like to thank Dr. Kolli Srinivas Garu, Principal of Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (V), Sidhout (M), YSR Kadapa-516 247, Andhra Pradesh, India.

Funding Support

The authors declare that they have no funding support for this study.

Conflict of Interest

The authors declare that there is no conflict of interest.

REFERENCES

[1] Peter J. Watts and Lisbeth Lllum. Colonic Drug Delivery. *Drug Development and Industrial Pharmacy*, 23(9):893–213, 1997.

[2] S D Gandhi, P R Pandya, N N Upadhyay, and N Upendra. Design, formulation and evaluation of a colon specific drug delivery system for a model anthelminthic drug-ivermectin. *Journal of Chemical and Pharmaceutical Research*, 2(5):229–243, 2010.

[3] DeWen Liu, Huijie Yan, Yiming Kong, Yun You, Yanling Li, Lixin Wang, Yan Tong, and Jinyu Wang. Preparation of Colon-Targeted Acetylharpagide Tablets and its Release Properties in vivo and in vitro. *Frontiers in Pharmacology*, 9:832, 2018.

[4] Mayur M Patel. Cutting-edge technologies in colon-targeted drug delivery systems. *Expert Opinion on Drug Delivery*, 8(10):1247–1258, 2011.

[5] Thiruganesh Ramasamy, Uma Devi Subbaih Kandhasami, Himabindhu Ruttala, and Suresh Shanmugam. Formulation and evaluation of xanthan gum based aceclofenac tablets for colon targeted drug delivery. *Brazilian Journal of Pharmaceutical Sciences*, 47(2):299–311, 2011.

[6] H Rajpurohit, S Sharma, P Sharma, and A Bhandari. Polymers for colon targeted drug delivery. *Indian Journal of Pharmaceutical Sciences*, 72(6):689–696, 2010.

[7] Lalduhsanga Pachuau and Bhaskar Mazumder. Evaluation of Albizia procera gum as compression coating material for colonic delivery of budesonide. *International Journal of Biological Macromolecules*, 61:333–339, 2013.

[8] C S Kumari, M P Kumar, P Anitha, M Purushothaman, and S Neelima. Development and Evaluation of Colon Targeted compressed Coating tablets of Etodolac. *Journal of Global Trends in Pharmaceutical Sciences*, 7(4):3512–3519, 2016.

[9] Takeshi Goto, Norifumi Tanida, Takaaki Yoshinaga, Shuji Sato, D. J. Ball, I. R. Wilding, Eiji Kobayashi, and Akio Fujimura. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans. *Journal of Controlled Release*, 97(1):31–42, 2004.

[10] B. Bharaniraja, K. Jayaram Kumar, C. M. Prasad, and A. K. Sen. Modified katira gum for colon targeted drug delivery. *Journal of Applied Polymer Science*, 119(5):2644–2651, 2011.

[11] Jianzhong Zhu, Li Zhong, Wenxue Chen, Yizhe Song, Zhengming Qian, Xianying Cao, Qiang Huang, Bin Zhang, Haiming Chen, and Weijun Chen. Preparation and characterization of pectin/chitosan beads containing porous starch embedded with doxorubicin hydrochloride: A novel and simple colon targeted drug delivery system. *Food Hydrocolloids*, 95:562–570, 2019.

[12] A Kumar, A Kaundal, M Ashawat, V Pandit, and P Kumar. Colon Targeted Pulsatile Drug Delivery System of Venlafaxine Hydrochloride for Treatment of Depression. *Current Psychopharmacology*, 6(1):59–73, 2017.

[13] Xia Wang, Deng-Guang Yu, Xiao-Yan Li, S. W. Annie Bligh, and Gareth R. Williams. Electrospun medicated shellac nanofibers for colon-targeted drug delivery. *International Journal of Pharmaceutics*, 490(1-2):384–390, 2015.

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Cite this article: Shaik Nissar, Pradeep Kumar M, Chandrakala P, Hari Kumar C. Preparation of Colon-Targeted Avermectins Tablets and its Release Properties *in vitro* Studies. Future J. Pharm. Health. Sci. 2022; 2(1): 29-34.

© 2022 Pharma Springs Publication.